3 Long-Term Growth Stocks to Build a Fortune by 2030

In the ever-evolving landscape of global markets, investors seeking compounding returns over the next decade must prioritize companies with durable competitive moats, scalable business models, and a relentless focus on innovation. Amazon, Vertex Pharmaceuticals, and TJX Companies exemplify this trifecta, leveraging technological advancements, market dominance, and strategic reinvention to secure their positions as long-term growth engines.

1. Amazon: The AI-Powered E-Commerce and Cloud Behemoth

Amazon's dominance in cloud computing and retail is underpinned by its strategic reinvention through artificial intelligence (AI). As of Q3 2025, Amazon Web Services (AWS) remains the crown jewel of its empire, . , directed toward AI infrastructure such as custom chips (e.g., Trainium3) and massive compute clusters like Project Rainier according to market analysis. These investments not only solidify AWS's leadership in the cloud market but also position Amazon as a critical enabler of enterprise AI adoption.

In retail, Amazon's AI-driven innovations are reshaping customer engagement. The AI-powered shopping assistant, Rufus, has 250 million active users, with users . Meanwhile, . locations has boosted customer satisfaction and retention. Financially, Amazon's Q3 2025 results highlight its strength: $180.2 billion in net sales and $21.2 billion in net income, driven by a . CEO Andy Jassy's emphasis on AI integration across logistics and customer service underscores Amazon's commitment to operational efficiency and long-term scalability according to industry analysis.

2. Vertex Pharmaceuticals: Pioneering Precision Medicine and Therapeutic Expansion

Vertex Pharmaceuticals has cemented its leadership in cystic fibrosis (CF) with a portfolio that treats 95% of patients in core markets. , , driven by demand for therapies like ALYFTREK and TRIKAFTA according to financial reports. The company's innovation extends beyond CF: its renal pipeline, including povetacicept for IgA nephropathy, is on track for FDA submission by year-end 2025 as reported in earnings. This diversification into renal diseases, alongside early-stage products like CASGEVY and JOURNAVX, creates a robust growth trajectory.

Vertex's financial discipline is equally compelling. Despite increased R&D spending , the company maintains a strong balance sheet and revised full-year revenue guidance . CEO Reshma Kewalramani's vision to address the last 5% of CF patients with no CFTR protein production highlights Vertex's commitment to innovation according to earnings call transcripts. With a durable moat in high-margin, life-saving therapies and a pipeline targeting underserved markets, Vertex is poised to deliver compounding returns as it scales into new therapeutic areas.

3. TJX Companies: The Scalable Off-Price Retail Powerhouse

TJX Companies' off-price retail model has proven remarkably resilient, according to investor reports. The company's global sourcing machine and flexible buying strategy enable it to offer high-quality merchandise at discounts of 20–60% compared to department stores as noted in investor materials. This model, combined with a price gap advantage over competitors, creates a durable moat in a sector where consumer demand for value remains strong.

TJX's scalability is further amplified by its expansion plans: from 5,000 stores globally to a long-term target of 7,000, including entry into Spain as reported in investor presentations. Its dual focus on brick-and-mortar and e-commerce platforms ensures adaptability to shifting consumer preferences. Financially, TJX's strong cash flow and high credit rating support aggressive shareholder returns, according to financial disclosures. This combination of operational efficiency, geographic expansion, and disciplined capital allocation positions TJX as a compounding machine in the retail sector.